ATLnsider,
Every major hint came after the screening hold. The hold started at about 300 enrolled which I believe made allowance for perhaps one last placebo patient scheduled for enrollment by the day of the hold and then enrollment continued to 331 instead of 348. That was the connection to “good” trial news turned into “bad”short term investment news ie “bump in the road”. Smart money “knows” that the double bottom was “set” in a flash by market makers earlier this year and that we are on the back side of the W formed by the successful small biotech model. I have been in biotechs for over 20 years and have done deep due diligence on the science. The science always wins even if any individual company might succumb to the economic pressure created by success along the way. ENMD had the science but not the resources so Celgene ended up being the giant that swallowed up ENMD. NWBO and retail shareholders have fought their way through the gauntlet and will be rewarded very well in short order. Harry Callahan got the bus and the witness to the court house and Linda Powers got this ship to the dock. It wasn’t pretty but now, with everyone watching, the truth gets told. Best wishes.
Market Data 
Markets 
AI
